Gravity Analytica

Exagen to Announce Third Quarter 2024 Results on November 12, 2024

XGN 10.29.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-12

Name of Upcoming Event:Earnings Conference Call

Full Press Release SEC Filings Our XGN Tweets

About Gravity Analytica

Recent Filings

PDF Version

CARLSBAD, Calif.,Oct. 29, 2024(GLOBE NEWSWIRE) --Exagen Inc.(Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter endedSeptember 30, 2024, before the market opens onTuesday, November 12, 2024.John Aballi, Exagen’s President and Chief Executive Officer, andJeff Black, Chief Financial Officer, will host a conference call to review the Company’s results at8:30 AM ET(5:30 AM PT).

Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). Participants wishing to access the call via webcast should use the link posted on theExageninvestor relations website atinvestors.exagen.com.

A replay of the conference call will be available untilTuesday, November 26, 2024, at11:59 PM ET(8:59 PM PT). Interested parties may access the replay of the conference call by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13749452. Additionally, a recording of the webcast will be available using the link on theExageninvestor relations website approximately one hour after the call concludes.

About Exagen Inc.

Exagen Inc.(Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based inSan Diego County, Calif., Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care,Exagenis dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, visitExagen.comor follow @ExagenInc onX.

Contact:Ryan DouglasExagen Inc.ir@exagen.com760.560.1525

Source: Exagen Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com